Article

A high sensitivity assay is more accurate than a classical assay for the measurement of plasma CRP levels in endometriosis.

Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium.
Reproductive Biology and Endocrinology (Impact Factor: 2.41). 08/2011; 9:113. DOI: 10.1186/1477-7827-9-113
Source: PubMed

ABSTRACT Endometriosis is associated with chronic subclinical inflammation. C-reactive protein (CRP), a marker of inflammation, could serve as a biomarker of endometriosis. We tested the hypothesis that a high sensitivity CRP assay (hsCRP) is more accurate than a classical CRP assay in the detection of subclinical inflammation in plasma of women with endometriosis.
CRP levels were measured by hsCRP and classical CRP assays in plasma of 204 women with endometriosis and 91 women without endometriosis. Both assays were compared with respect to their value for the diagnosis of endometriosis.
The number of plasma samples with detectable CRP was significantly higher (100%) using the hsCRP assay when compared to the classical CRP assay (42.7%) (p < 0.0001). Significantly increased CRP plasma levels were found in women with endometriosis when compared with controls when the hsCRP assay was used in samples obtained during the luteal phase (p = 0.008). The highest discriminative ability for the diagnosis of endometriosis was also obtained using the hsCRP assay during the luteal phase, especially for moderate -severe endometriosis. At a cut-off level of hsCRP > 0.71 mg/L, moderate-severe stages were diagnosed with 80.7% sensitivity and 63.9% specificity during the luteal phase. Using a similar cut-off value for CRP analyzed by the classical method, moderate-severe endometriosis was diagnosed with lower sensitivity (67.7%, p = 0.06) and comparable specificity (63.9%).
The hsCRP assay was superior to the classical CRP assay for the detection of low CRP levels and for revealing subclinical inflammation in plasma of women with endometriosis.

0 Bookmarks
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenesis of endometriosis is associated with an inflammatory process. Here, we assessed if the levels of high-sensitivity C-reactive protein (hs-CRP) in serum could constitute an effective method for detecting systemic inflammation during endometriosis. This was a prospective, laboratory-based study, which was carried out in a tertiary-care university hospital. Patients with histologically proven endometriosis (n=370) and unaffected women (n=464) were enrolled between January 2005 and December 2009. We performed complete surgical excision of endometriotic lesions with pathological analysis. In addition, hs-CRP levels were determined through a particle-enhanced immunoturbidimetric method. Hs-CRP levels were measured in both controls and women with endometriosis according to the established surgical classifications of endometriosis: superficial (SUP), endometrioma (OMA), and deep infiltrating endometriosis (DIE). Also, hs-CRP levels were evaluated according to hormonal treatment and menstrual cycle. Hs-CRP serum levels did not statistically differ between women with endometriosis and controls (median in ng/mL [range]: 0.82 [0.04-42.89] vs. 0.9 [0.03-43.73], respectively; p=0.599). Moreover, subgroup analysis revealed no difference between SUP, OMA, DIE, and controls: 0.8 (0.15-13.35), 0.81 (0.04-38.82), 0.83 (0.09-42.89), and 0.9 (0.03-43.73), respectively (p=0.872). Furthermore, no effect was observed regarding hormonal treatment or menstrual cycle. Although endometriosis is an inflammatory disease, we failed to identify any systemic changes in hs-CRP serum levels. Therefore, hs-CRP analysis appears to be irrelevant to the diagnosis and staging of endometriosis.
    American journal of obstetrics and gynecology 01/2014; · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometriosis affects 10% of premenopausal women and 35-50% of women with infertility, pelvic pain, or both. At present, endometriosis can only be diagnosed with surgery, where laparoscopy is considered a gold standard. Noninvasive biomarkers are thus urgently needed. In 2010, the peripheral biomarkers of endometriosis were systematically reviewed by May et al. However, with the introduction of '-omics' technologies, we have witnessed immense progress in biomarker discovery, which now calls for an overview of recent studies. This report looks at potential blood and urine biomarkers of endometriosis published in the last 3 years. The current status of noninvasive diagnostic biomarkers of endometriosis is discussed, with the limitations of these studies identified and recommendations for future biomarker discovery provided.
    Expert Review of Molecular Diagnostics 04/2014; 14(3):365-85. · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometriosis is a complex gynaecological disease, characterized by the presence and growth of endometrial tissue outside the uterus, resulting in pelvic pain and infertility. It occurs in 10% of women in their reproductive age. The viable endometrial cells enter the peritoneal cavity by retrograde menstruation, implant and cause lesions ectopically; depending on their ability to survive, attach, grow and invade. These 'normal' endometrial cells turn 'endometriotic' apparently because of inherent abnormalities present in them. Information on these molecular abnormalities is now being sought through proteomic approaches. Recent proteome-based comparisons between the eutopic endometrium from normal women and patients with endometriosis have revealed several proteins (many of which are shown to have a role in several cancers), of which a few have been validated as potential players in the etiology of endometriosis. After an initial in-flow of information from these proteome studies of eutopic endometrium, focus now needs to be expanded to the changes in the various protein post-translational modifications and their upstream effectors present in these tissues. Early diagnosis of endometriosis through non-invasive means is the need of the hour as well - which would require the use of the presently existing immunoassays, along with the advancing mass-spectrometry- based proteomics. In this review, we aim to discuss these future thrust areas of human endometriosis proteomics and also present the proteomic advances made so far in understanding the molecular basis of endometriosis. This article is protected by copyright. All rights reserved.
    PROTEOMICS - CLINICAL APPLICATIONS 07/2013; · 1.81 Impact Factor

Full-text (2 Sources)

Download
30 Downloads
Available from
Jun 2, 2014